Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

84 results about "Thyroid Hormone Receptor Agonists" patented technology

Crystal form of thyroid hormone receptor stimulant as well as preparation method and application of crystal form

The invention aims to provide a crystal form of a thyroid hormone receptor agonist, a preparation method, a pharmaceutical composition and application of the crystal form in preparation of a TRbeta selective agonist medicine. Compared with the prior art, the crystal form provided by the invention has one or more improved properties, and is of great significance to further development of the medicine.
Owner:CHENGDU HONGDA PHARM CO LTD

Thyroid hormone receptor beta agonist compounds

PendingUS20250236615A1Organic chemistryMetabolism disorderThyroid hormone receptor betaAgonist
Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.
Owner:TERNS INC

Combinations of GLP-1r and THRß agonists and methods of use thereof

PendingUS20240398794A1Metabolism disorderPeptide/protein ingredientsThyroid hormone receptor betaAgonist
Provided herein are combinations comprising a glucagon-like peptide-1 receptor (GLP-1R) agonist and a thyroid hormone receptor beta (THRβ) agonist and methods comprising administering to a subject in need thereof such combinations.
Owner:TERNS PHARMACEUTICALS INC

Compounds and their uses as thyroid hormone receptor agonists

A compound of formula (I) or (Ia), or a tautomer or a pharmaceutically acceptable salt thereof is provided. Compounds of formula (II) to (V), or a tautomer or a pharmaceutically acceptable salt thereof are also provided. These compounds and the pharmaceutical compositions containing them are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto. (I), (Ia)
Owner:NANJING RUIJIE PHARMATECH CO LTD

Combinations of GLP-1R and THRβ agonists and methods of use thereof

ActiveUS12485118B2Metabolism disorderPeptide/protein ingredientsThyroid hormone receptor betaAgonist
Provided herein are combinations comprising a glucagon-like peptide-1 receptor (GLP-1R) agonist and a thyroid hormone receptor beta (THRβ) agonist and methods comprising administering to a subject in need thereof such combinations.
Owner:TERNS PHARMACEUTICALS INC

Combination therapies of FASN inhibitors with thyroid hormone receptor agonists

Therapeutic combinations of fatty acid synthesis modulators and thyroid hormone receptor agonists are provided. The combinations may be used to treat disorders including metabolic disorders and liver disorders, such as nonalcoholic steatohepatitis / metabolic dysfunction-associated steatohepatitis (NASH / MASH).
Owner:SAGIMET BIOSCIENCES INC

Combinations of GLP-1r and THRß agonists and methods of use thereof

ActiveUS20250195512A1Metabolism disorderPeptide/protein ingredientsThyroid hormone receptor betaAgonist
Provided herein are combinations comprising a glucagon-like peptide-1 receptor (GLP-1R) agonist and a thyroid hormone receptor beta (THRβ) agonist and methods comprising administering to a subject in need thereof such combinations.
Owner:TERNS PHARMACEUTICALS INC

Combination therapies of FASN inhibitors with thyroid hormone receptor agonists

Therapeutic combinations of fatty acid synthesis modulators and thyroid hormone receptor agonists are provided. The combinations may be used to treat disorders including metabolic disorders and liver disorders, such as nonalcoholic steatohepatitis / metabolic dysfunction-associated steatohepatitis (NASH / MASH).
Owner:SAGIMET BIOSCIENCES INC

Methods of reducing side effects associated with thyroid

The present disclosure relates to methods of administering thyroid hormone receptor agonists. The present disclosure provides methods wherein the methods maintain the activity of a given thyroid receptor agonist in ameliorating or curing obesity, hyperlipidemia, hypercholesterolemia, diabetes, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, hypothyroidism, and related conditions, meanwhile, thyroid-related and thyroid axis-related side effects are reduced or eliminated.
Owner:VIKING THERAPEUTICS INC +1

4-quinazolinone compound serving as thyroid hormone beta receptor agonist and application of 4-quinazolinone compound

The invention belongs to the field of biological medicines, and particularly relates to 4-quinazolinone compounds serving as thyroid hormone beta receptor agonists and application of the 4-quinazolinone compounds. The invention discloses a thyroid hormone beta receptor agonist as shown in a formula (I), relates to a 4-quinazolinone compound and a preparation method thereof, and further relates to a pharmaceutical composition containing the compound and application. The compound or the pharmaceutical composition provided by the invention can be used for preventing, treating or relieving diseases regulated by thyroid hormone beta receptors, especially for treating non-alcoholic fatty liver diseases.
Owner:FUDAN UNIVERSITY

Compounds and their use as thyroid hormone receptor agonists

The present invention provides a compound of formula (I) or (la), or a tautomer or a pharmaceutically acceptable salt thereof, and further provides a compound of formula (II) to (V), or a tautomer or a pharmaceutically acceptable salt thereof. These compounds and pharmaceutical compositions containing them can be used to treat diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related conditions and diseases, and can be used for other diseases, such as NASH, atherosclerosis, cardiovascular disease, hypothyroidism, thyroid cancer and other related conditions and diseases. (I), (Ia) #imgabs0#
Owner:NANJING RUIJIE PHARMATECH CO LTD

Aryloxy indole formic acid compound as well as preparation method and application thereof

The invention relates to the field of biological medicine, in particular to an aryloxy indole formic acid compound as well as a preparation method and application thereof. The general formula (I) of the aryloxy indole carboxylic acid compound is shown in the specification, wherein R1 is a Cl atom or a Br atom; r2 and R3 are two methylene groups connected to the same oxygen atom, or R2 is any one of a methyl group, a methoxy group, an isopropyl group, a methylthio group and a hydrogen atom, and R3 is any one of a halogen atom, a methyl group, a methoxy group, an isopropyl group, a propoxy group, an isopropoxy group, a butoxy group, an isobutoxy group, a cyclopropyl methoxy group, a benzyl group, a benzyloxy group and a hydrogen atom. As a thyroid hormone receptor agonist, the aryloxy indole formic acid compound has good THRbeta selectivity and THRbeta agonist activity, has the advantages of low toxicity and good biological safety, and has high practical value.
Owner:SUZHOU AOXIN BIOPHARMACEUTICAL CO LTD

A compound as a thyroid hormone beta receptor agonist and its use

The present invention relates to a compound that acts as a thyroid hormone beta receptor agonist and its use, and further relates to a compound represented by formula (1) or a pharmaceutically acceptable form thereof, a pharmaceutical composition comprising the same, and a method for preparing the same. The compound or pharmaceutical composition described herein can be used to prepare a medicament for preventing, treating, or alleviating diseases regulated by thyroid hormone beta receptors. #imgabs0#
Owner:CASCADE (SHANGHAI) PHARMA TECH CO LTD

A thyroid hormone receptor β agonist compound and its preparation method and application

ActiveCN115838354BOrganic active ingredientsSenses disorderThyroid hormone receptor betaPharmaceutical drug
The present invention provides a thyroid hormone receptor β (TRβ) agonist compound, a preparation method and an application thereof. The compound and the pharmaceutically acceptable salts, esters, amides or carbamates, as well as isomers, racemates, prodrugs, co-crystallized complexes or solvates of the compound can be used as thyroid hormone receptor β agonists, and the prepared thyroid hormone receptor β agonist has a good activation effect on wild-type and mutant thyroid hormone receptor β, has a weak effect or basically no effect on thyroid hormone receptor α (TRα) and prolyl hydroxylase (PHD2) targets, and has good selectivity. Therefore, the compound can be used in the prevention or treatment of thyroid hormone receptor β-mediated related diseases.
Owner:GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH CHINESE ACADEMY OF SCIENCES

Thyroid hormone receptor beta agonist compounds

ActiveUS12398127B2Organic chemistryEndocrine system disorderThyroid hormone receptor betaAgonist
Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.
Owner:TERNS PHARMACEUTICALS INC

Novel thyroid hormone beta receptor agonists

The present application provides a novel thyroid hormone β receptor agonist of formula (I) having better activity, selectivity or safety and the use thereof for preventing or treating diseases related to the action of β receptor agonists, including, for example, obesity, hyperlipidemia, hypercholesterolemia, diabetes, liver diseases (fatty liver, NASH, NAFLD, etc.), cardiovascular diseases (atherosclerosis, etc.), thyroid diseases (hypothyroidism, thyroid cancer, etc.), and the like.
Owner:CHENGDU KANGHONG PHARMACEUTICAL GROUP CO LTD

Crystal of thyroid hormone .beta. receptor agonist, preparation method therefor and use thereof

Disclosed is a crystal of a thyroid hormone <com:Math><semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>< / com:Math> receptor agonist, a process for preparing the same and use thereof. The crystal is a compound of formula I, having diffraction peaks at <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math> angles using Cu-K<com:Math><semantics>α<annotation encoding="application / x-tex">\alpha< / annotation>< / semantics>< / com:Math> radiation of 12.124 <com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> 0.2, 15.483 <com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> 0.2, 16.38 <com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> 0.2, 16.666 <com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> 0.2, 19.089 <com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> 0.2, <com:Math><semantics>20.415±0.2<annotation encoding="application / x-tex">20.415 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>20.821±0.2<annotation encoding="application / x-tex">20.821 \pm 0.2< / annotation>< / semantics>< / com:Math> in an X-ray power diffraction pattern, [Image disponible dans le document PDF, Image available in the PDF document] Ι The crystal has basically no hygroscopicity, a relatively small crystal particle size and a relatively large drug specific surface area can improve the dissolution rate of drugs, is beneficial to the absorption of drugs and improves the bioavailability.
Owner:GANNEX PHARMA CO LTD

Thyroid hormone receptor agonists and use thereof

The application relates to a compound of Formula (I′) or (I):or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of thyroid hormone receptors, a pharmaceutical composition comprising a compound of Formula (I′) or (I), and a method of treating or preventing a disease or disorder regulated by thyroid hormone.
Owner:ECCOGENE INC

Thyroid hormone receptor beta agonist compounds

ActiveJP2025020206AOrganic active ingredientsOrganic chemistryDiseaseThyroid hormone receptor beta
To provide thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.SOLUTION: For example, the following compound (example 2) is illustrated.SELECTED DRAWING: None
Owner:TERNS PHARMACEUTICALS INC

THR-beta modulators, alone or in combination with GLP-1r\GIPR\GCGR modulators for the treatment of metabolic diseases and alopecia areata diseases

PCT designated stageWO2026092583A1Organic active ingredientsMetabolism disorderDiseaseThyroid hormone receptor beta
Provided herein are method of thyroid hormone receptor beta (THRβ) agonist and combinations comprising a glucagon-like peptide-1 receptor (GLP-1R) agonist and a thyroid hormone receptor beta (THRβ) agonist and methods comprising administering to a subject in need thereof such combinations.
Owner:ASCLETIS PHARMA (CHINA) CO LTD

Thyroid hormone receptor agonists

Provided herein are novel thyroid hormone receptor (TR) agonists, e.g., having Formula I, II, or III. Also provided are methods of preparing the novel TR agonists and method of using the novel TR agonists for treating diseases or disorder modulated by TR agonists, such as NAFLD, NASH, diabetes, hyperlipidemia and / or hypercholesterolemia.
Owner:INVENTISBIO CO LTD

Culture medium with composition

ActiveCN114729312BEffective differentiation inductionCulture processSkeletal/connective tissue cellsPhosphodiesterase inhibitorBrown adipocyte differentiation
The present application provides a novel medium composition for use in inducing differentiation of somatic cells into brown adipocytes. As the present application, for example, there can be mentioned a medium composition for use in inducing differentiation of somatic cells into brown adipocytes, which is characterized by comprising seven components of a thyroid hormone receptor agonist, a glucocorticoid receptor agonist, a phosphodiesterase inhibitor, insulin, an ascorbic acid derivative, albumin, and an antibiotic. According to the present application, differentiation induction of somatic cells into brown adipocytes can be effectively performed. In addition, according to the present application, brown adipocytes can be effectively maintained.
Owner:KATAOKA +1